一分钟看懂
这是一项关于结直肠癌的I 期研究，登记的药物或干预包括NG-350A IV administration；Capecitabine oral administration；Radiotherapy，当前状态为研究进行中，已停止招募。登记地点显示中国Los Angeles、Orlando、St Louis、Columbus等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
NG-350A IV administration；Capecitabine oral administration；Radiotherapy · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- University of Southern California · Los Angeles
- AdventHealth Orlando · Orlando
- Washington University School of Medicine · St Louis
- Ohio State University Comprehensive Cancer Center · Columbus
- The University of Texas MD Anderson Cancer Center · Houston
- University College London NHS FT · London
- The Royal Marsden NHS Foundation Trust · Sutton
公开的入选条件
- * Histologically confirmed adenocarcinoma of the rectum.
- * Locally advanced disease (clinical stage II-III based on pelvic MRI) selected by a multidisciplinary team for treatment with neoadjuvant CRT (which may be followed by CNCT to comprise planned TNT). Patients with oligometastatic disease are permitted provided
- * Confirmed microsatellite stable (MSS)/proficient mismatch repair (pMMR) status.
- * Provide written informed consent to participate.
- * ECOG Performance Status 0 or 1.
- * Must not be pregnant or breastfeeding.
- * Patients who are sexually active (with either sex) must agree to comply with contraceptive requirements.
- * Adequate lung reserve, renal function, hepatic function, and bone marrow/hematological function assessed ≤ 10 days prior to first dose.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06459869；登记信息更新于 2026-09-16。